Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Given Average Recommendation of "Moderate Buy" by Brokerages

Key Points

• "Moderate Buy" consensus from seven analysts (six buy, one sell) with an average 12‑month price target of $31.80; several firms recently raised targets, notably Jefferies to $42.
• Shares opened at $16.90, the company has a market cap of $1.42 billion, a one‑year range of $2.54–$26.95, and 50/200‑day moving averages of $16.13 and $10.43, respectively.
• Corvus is a clinical‑stage immuno‑oncology biopharma focused on therapies that inhibit the adenosine pathway to counter tumor‑driven immunosuppression.

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the seven analysts that are presently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating and six have assigned a buy rating to the company. The average twelve-month price target among analysts that have covered the stock in the last year is $31.80.

Several research firms have recently commented on CRVS. Jefferies Financial Group upped their price target on shares of Corvus Pharmaceuticals from $13.00 to $42.00 and gave the stock a "buy" rating in a research report on Thursday, January 22nd. Cantor Fitzgerald reissued an "overweight" rating on shares of Corvus Pharmaceuticals in a research note on Thursday, December 11th. Oppenheimer upped their target price on shares of Corvus Pharmaceuticals from $15.00 to $32.00 and gave the stock an "outperform" rating in a research report on Wednesday, January 21st. Barclays raised their price target on shares of Corvus Pharmaceuticals from $16.00 to $28.00 and gave the company an "overweight" rating in a research note on Tuesday, January 20th. Finally, HC Wainwright lifted their price target on Corvus Pharmaceuticals from $11.00 to $27.00 and gave the company a "buy" rating in a report on Tuesday, January 20th.

Corvus Pharmaceuticals Price Performance

Shares of NASDAQ CRVS opened at $16.90 on Thursday. The firm has a market capitalization of $1.42 billion, a PE ratio of -31.89 and a beta of 0.78. Corvus Pharmaceuticals has a 1-year low of $2.54 and a 1-year high of $26.95. The business's fifty day moving average price is $16.13 and its two-hundred day moving average price is $10.43.

Institutional Trading of Corvus Pharmaceuticals

Several hedge funds have recently added to or reduced their stakes in CRVS. Mirae Asset Global Investments Co. Ltd. boosted its position in Corvus Pharmaceuticals by 26.0% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,629 shares of the company's stock worth $28,000 after acquiring an additional 748 shares during the period. ProShare Advisors LLC increased its holdings in shares of Corvus Pharmaceuticals by 7.7% during the fourth quarter. ProShare Advisors LLC now owns 13,764 shares of the company's stock valued at $106,000 after purchasing an additional 979 shares during the period. Price T Rowe Associates Inc. MD raised its stake in shares of Corvus Pharmaceuticals by 5.2% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 34,105 shares of the company's stock valued at $263,000 after purchasing an additional 1,696 shares in the last quarter. JPMorgan Chase & Co. lifted its holdings in Corvus Pharmaceuticals by 6.0% in the third quarter. JPMorgan Chase & Co. now owns 32,232 shares of the company's stock worth $238,000 after purchasing an additional 1,812 shares during the period. Finally, Shelton Wealth Management LLC lifted its holdings in Corvus Pharmaceuticals by 13.8% in the fourth quarter. Shelton Wealth Management LLC now owns 15,638 shares of the company's stock worth $120,000 after purchasing an additional 1,896 shares during the period. Institutional investors own 46.64% of the company's stock.

Corvus Pharmaceuticals Company Profile

Corvus Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation immuno-oncology therapies. The company's research efforts are centered on harnessing both the innate and adaptive immune systems to counteract tumor-driven immunosuppression. By targeting key pathways that regulate immune cell function, Corvus aims to create novel agents that can be combined with existing cancer treatments to improve patient outcomes.

Corvus's lead pipeline candidates include small-molecule and antibody therapies designed to inhibit the adenosine pathway, a known mediator of tumor immune escape.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.